KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) Research & Development (2016 - 2026)

Abbott Laboratories' Research & Development history spans 18 years, with the latest figure at $767.0 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 7.12% to $767.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.0 billion, a 4.07% increase, with the full-year FY2025 number at $2.9 billion, up 3.45% from a year prior.
  • Research & Development hit $767.0 million in Q1 2026 for Abbott Laboratories, up from $735.0 million in the prior quarter.
  • Over the last five years, Research & Development for ABT hit a ceiling of $782.0 million in Q3 2022 and a floor of $654.0 million in Q1 2023.
  • Historically, Research & Development has averaged $716.6 million across 5 years, with a median of $715.0 million in 2023.
  • Biggest five-year swings in Research & Development: rose 16.37% in 2022 and later fell 14.07% in 2023.
  • Tracing ABT's Research & Development over 5 years: stood at $725.0 million in 2022, then decreased by 3.45% to $700.0 million in 2023, then grew by 7.0% to $749.0 million in 2024, then decreased by 1.87% to $735.0 million in 2025, then rose by 4.35% to $767.0 million in 2026.
  • Business Quant data shows Research & Development for ABT at $767.0 million in Q1 2026, $735.0 million in Q4 2025, and $766.0 million in Q3 2025.